On March 20 we will hear from the new management of Star, perhaps to become Rock Creek. This is an open meeting to which analysts, stockholders, and other interested parties are invited. We now have on staff a specialist at communicating with institutional investors. This meeting will be held at Roskamp, and that will be impressive. I would not want to be short as the date of this meeting approaches.
The overwhelming fact the shorts are up against is that the alleviation of physical degeneration and pain is a cause with massive support, and that anatabine delivers major benefits to most who try it.
The reason is simple: anatabine is one of the most powerful anti-inflammatories ever discovered. This simple fact is not going away. It's foolish and financially dangerous to stand in the way.
Such opposition, when put into effect by risking money going short, is like betting on a successful crossing of a heavily mined field, where each mine could be thought of as a success with regulators, an announcement of an alliance for funding or development, a new market opportunity, or the appearance of a new investor whose understanding of biotech is highly regarded. There is too much chance of unexpected good news to make opposition (through financial commitment) a good risk.
AI
